NASDAQ:JAN JanOne (JAN) Stock Price, News & Analysis → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free JAN Stock Alerts $2.95 -0.89 (-23.18%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$2.81▼$3.7950-Day Range$2.36▼$5.1052-Week Range$0.22▼$5.26Volume567,247 shsAverage Volume266,947 shsMarket Capitalization$26.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get JanOne alerts: Email Address Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. About JanOne Stock (NASDAQ:JAN)JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Read More JAN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAN Stock News HeadlinesMay 13 at 5:14 PM | msn.comWhy Tevogen Bio Holdings Stock Is Moving Higher TodayMay 13 at 10:22 AM | markets.businessinsider.comJanOne To Buy Block Chain Fintech Provider ALT 5 Sigma In All-stock Deal; JAN Up In Pre-marketMay 10, 2024 | finance.yahoo.comJanOne to Acquire ALT 5 Sigma Inc., a Leading Next Generation Blockchain Financial Technology ProviderMay 3, 2024 | markets.businessinsider.comJAN Stock Earnings: JanOne Reported Results for Q1 2024March 15, 2024 | prnewswire.comJanOne Regains Compliance with Nasdaq's Listing RequirementsFebruary 13, 2024 | msn.comWhy ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketFebruary 9, 2024 | msn.comJanOne, Inc. Revises Promissory Notes and Issues New DebtDecember 23, 2023 | morningstar.comJanOne Inc JANNovember 9, 2023 | msn.comWhy Is Assertio (ASRT) Stock Down 39% Today?November 7, 2023 | nj.comN.J. general election results 2023: Morris CountySeptember 21, 2023 | finance.yahoo.comJanOne to Present at the Dawson James 8th Annual Investment ConferenceAugust 31, 2023 | finance.yahoo.comJanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment ConferenceAugust 29, 2023 | marketwatch.comJanOne Shares Jump 16% After Obtaining U.S. Patent for Jan123 to Treat Chronic PainAugust 29, 2023 | finance.yahoo.comJanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic PainAugust 25, 2023 | finance.yahoo.comJanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual MeetingAugust 22, 2023 | finance.yahoo.comJanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq RulesAugust 18, 2023 | finance.yahoo.comJanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq RulesAugust 18, 2023 | finance.yahoo.comJanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual MeetingJune 28, 2023 | markets.businessinsider.comJanOne Files Intl Patent Application For Low Dose Naltrexone For Chronic PainJune 28, 2023 | finance.yahoo.comJanOne files international patent application for methods of using low dose naltrexone to treat chronic painApril 18, 2023 | finance.yahoo.comJanOne Completes Pre-IND Meeting with FDA on Jan123April 13, 2023 | finance.yahoo.comJanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023March 24, 2023 | finance.yahoo.comJanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-MarketMarch 24, 2023 | msn.comWhy Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 23, 2023 | benzinga.comJanOne shares are trading lower after the company announced a registered direct offering of common stock priced at-the-market.See More Headlines Receive JAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JanOne and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/14/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JAN CUSIPN/A CIK862861 Webwww.janone.com Phone(702) 997-5968Fax952-930-1800Employees199Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-359.71% Return on Assets-70.26% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual Sales$39.61 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-4.40Miscellaneous Outstanding Shares8,980,000Free Float8,707,000Market Cap$26.49 million OptionableNot Optionable Beta2.04 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Tony Isaac (Age 70)President, CEO, Corporate Secretary & Director Comp: $625.32kMr. Virland A. Johnson CPA (Age 61)Chief Financial Officer Comp: $250.32kDr. Tony Giordano Ph.D.Chief Scientific OfficerMs. Cyndy L. JanzigDirector of Human ResourcesDr. Douglas FlanaganChief Formulation AdvisorKey CompetitorsDURECTNASDAQ:DRRXProMIS NeurosciencesNASDAQ:PMNApollomicsNASDAQ:APLMMarker TherapeuticsNASDAQ:MRKRCASI PharmaceuticalsNASDAQ:CASIView All Competitors JAN Stock Analysis - Frequently Asked Questions How have JAN shares performed in 2024? JanOne's stock was trading at $0.5550 at the start of the year. Since then, JAN stock has increased by 431.5% and is now trading at $2.95. View the best growth stocks for 2024 here. When is JanOne's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024. View our JAN earnings forecast. How do I buy shares of JanOne? Shares of JAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JAN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Crypto 9-5 Escape PlanCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JanOne Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
